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Introduction
Combination chemotherapy is capable of eliminating clinically apparent disease and inducing complete remission (CR) in the majority of patients with acute myeloid leukemia (AML). 1 However, it is often ineffective at eliminating minimal residual disease (MRD). 2 Consequently, the majority of patients relapse within 2 years of treatment. Currently, treatment options to prevent relapse of leukemia include allogeneic or autologous hematopoietic cell transplantation (HCT). Allogeneic HCT is the treatment of choice for younger patients with high and intermediate risk disease who are medically fit and have a suitable donor. [3] [4] [5] Unfortunately, allogeneic HCT can cause debilitating graft-versus-host disease. Compared with allogeneic HCT, autologous HCT has a lower transplant-related mortality but is associated with a higher relapse rate due to the lack of an immune-mediated graft-versus-leukemia effect. Infusion of unselected donor lymphocytes to treat relapse after HCT is effective in a minority of patients but rarely produces durable remission of disease. [6] [7] [8] Novel cellular therapies that can effectively eliminate MRD during chemotherapy-induced remission without causing severe damage to the host are needed to prevent disease relapse and improve long-term survival of AML patients. Adoptive cell therapy using ex vivo activated and expanded autologous T cells with potent anti-tumor activity could be an effective complementary approach to chemotherapy for eliminating residual tumor cells. The majority of T cells in human peripheral blood (PB) express either CD4 or CD8 molecules. Approximately 1-3% of them express CD3 but lack CD4, CD8 and CD56, and are termed double negative T (DNT) cells. The DNT cells may express either an ab-or a gd-T cell receptor (TCR). Unlike tumor-infiltrating lymphocytes or cytokine-activated killer cells whose anti-tumor effects have been investigated extensively, [9] [10] [11] [12] [13] little is known about the role of DNT cells in tumor immunity. Previously, we have demonstrated in mouse models that a single infusion of pre-activated allogeneic ab-DNT cells or clones could protect mice from a lethal dose of leukemia cells without causing graft-versus-host-disease. 14, 15 In addition, a human ab-DNT cell clone isolated from PB of a melanoma patient was shown to be able to kill gp-100-expressing melanoma cells. 16 It is also known that human pan gd-T cells have potent anti-tumor effects. 17 However, due to the limited number of primary DNT cells that can be obtained in the blood and the lack of effective methods to expand this cellular population, the role of human DNT cells in anti-tumor responses remains elusive.
To evaluate the anti-tumor effect of human DNT cells, we developed a novel protocol to efficiently expand human DNT cells ex vivo. We found that DNT cells could be expanded to clinically useful numbers in a majority of AML patients during or just after the period of consolidation chemotherapy and that expanded DNT cells were effective in killing both allogeneic and autologous leukemic cells in vitro. The results obtained from these studies provide evidence that ex vivo expanded autologous DNT cells could be used as a novel immunotherapy to complement cytotoxic chemotherapy to prevent AML relapse by eliminating residual leukemic cells.
Materials and methods

Patient population
The study was approved by the University Health NetworkResearch and Ethics Board (UHN-REB). Eligible patients included patients aged 18 years or older with AML in CR after standard chemotherapy. One month after conventional induction or consolidation chemotherapy, 20 ml of whole blood was drawn from AML patients.
Leukemic blasts and cell lines
Bone marrow or PB samples were obtained from newly diagnosed AML patients in the clinic under an UHN-REB approved protocol after obtaining appropriate informed consent. For in vitro studies, CD34 þ cells were purified using CD34-FITC and anti-FITC-coated magnetic beads (Miltenyi Biotec, Auburn, CA, USA) with 495% purity, and used as targets in standard 51 Cr-release assays. U937 (histiocytic lymphoma) cell line was obtained from the American Type Culture Collection (Manassas, VA, USA). Primary leukemic cell lines OCI/AML-2 (AML-2) and OCI/AML-3 (AML-3) were generated from AML patients as described previously. 18, 19 All cell lines were cultured in RPMI-1640 supplemented with 10% fetal bovine serum, and incubated at 37 1C in 5% CO 2 .
Ex vivo expansion of human DNT cells
To enrich DNT cell population, CD4
þ and CD8 þ cells together with red blood cells were depleted using RosetteSep depletion kit according to the manufacturer's instruction (StemCell Technologies, Vancouver, BC, Canada). CD4-and CD8-depleted PB mononuclear cells were either frozen viable for future use, or cultured fresh in 24-well plates with anti-CD3 monoclonal antibody (OKT3, 5 mg/ml, eBioscience Inc., San Diego, CA, USA) in complete medium supplemented with recombinant human interleukin 2 (rhIL-2) (250 U/ml; Chiron, Canada ULC, Québec, Canada) and rhIL-4 (0.1 ng/ml, Biosource, Camarillo, CA, USA). The cells were washed and cultured with fresh media plus cytokines and soluble anti-CD3 antibody on day 7. On day 14, cells were harvested, counted and their viability, composition and purity were assessed by flow cytometry. The expanded DNT cells were either used directly or further purified by depleting CD4 þ and CD8 þ and CD56 þ T cells before their use. In some experiments, DNT cells were further separated into ab-DNT and gd-DNT cells by FACS.
Antibodies and flow cytometry
The following anti-human antibodies for staining of cell surface markers and intracellular molecules were used: CD3-FITC, -PECy5 or -PECy7, CD4-FITC or -PE, CD8-FITC or -PE, CD34-FITC, CD56-PECy7, pan ab-TCR-FITC, pan gd-TCRPECy5 or -FITC were purchased from Beckman Coulter (Mississauga, ON, Canada), and FasL-PE from eBiosciences Inc.; perforin-PE, Granzyme B-PE, interferon (IFN)-g-APC, tumor necrosis factor (TNF)-a-APC were from BD Biosciences (Mississauga, ON, Canada). Isotype-matched monoclonal antibodies were obtained from BD Biosciences and used as staining controls. For intracellular staining, cells were either stimulated with PMA/Ionomycin (Sigma-Aldrich, Oakville, ON, Canada) and GolgiSTOP (BD Biosciences) for 3 h for IFN-g and TNF-a staining or used without further stimulation for perforin and Granzyme B staining using Cytofix/Cytoperm Kit (BD Biosciences) according to the manufacturer's instruction. Data acquisitions were performed using either FC500 (Beckman Coulter) or FACSCalibur or LSRII (BD Biosciences) Flow cytometers and data were analyzed using FlowJo software (Tree Star, Inc., Ashland, OR, USA).
Cytotoxicity assay and blocking experiments
The cytotoxic activity of ex vivo expanded DNT cells was measured by standard 4-h 51 Cr release assay. Briefly, 10 6 target cells (either leukemic cell lines or freshly isolated leukemic blasts) were labeled with 100 mCi of 51 Cr for an hour, washed and coincubated with varying ratios of ex vivo expanded DNT cells. Percent specific target killing was calculated as described previously. 20 For cytotoxicity blocking experiments, DNT cells were incubated with 100 nM of Concanamycin A (CMA; SigmaAldrich) for 30 min and washed before co-incubation with targets.
Statistical analyses
Bar graphs were generated using Prism software (GraphPad, San Diego, CA, USA). Data were expressed as means ± s.d. The Student's t-test was used for statistical data analysis. Po0.05 was considered statistically significant.
Results
Patient characteristics
A total of 16 AML patients in CR were enrolled into this study at the Princess Margaret Hospital, Toronto, Canada. The median age of the patients was 54 (range, 36-69), 50% were females. Characteristics of the study patients are shown in Table 1 .
DNT cells can be expanded ex vivo from AML patients in CR during chemotherapy DNT cells comprise 1-3% of PB mononuclear cells from AML patients. To determine whether DNT cells can be used as a novel immunotherapy to improve AML patient survival by eliminating residual leukemic cells after CR, we first developed a method by which DNT cells could be expanded ex vivo. To prevent outgrowth of CD8 þ and CD4 þ T cells, CD4 þ and CD8 þ T cells were depleted together with red blood cells. The enriched DNT cells derived from 20 ml blood ranged from 2 to 5 Â 10 5 cells, and were activated by cross-linking their TCR with anti-CD3 monoclonal antibody for 3 days followed by addition of soluble anti-CD3 at day 7 for 3 days. The expanded cells were harvested on day 14. The total number of expanded cells and total number of DNT cells from each patient at different stages of chemotherapy are shown in Table 1 . From a total of 28 cultures from 16 AML patients, we were able to expand DNT cells from 13 out of 16 patients (81%) including 24 of the 28 (86%) cultures. For those patients whose DNT cells expanded, we obtained a mean of 43 Â 10 6 (range, 2-300 Â 10 6 ) DNT cells from 20 ml blood, or an average of a 478±331-fold expansion in two weeks. The composition of expanded cells was examined by flow cytometric analysis and the data from all cultures are shown in Supplementary Table 1 . We found that 94 ± 7% of expanded cells were CD3 þ T cells, 66±23% were DNT cells, 30 ± 20% were CD4 þ or CD8 þ T cells and about 5% were CD56 þ CD3 À natural killer cells. Representative data before and after expansion are shown in Figure 1 . These data show the feasibility of generating a large number of DNT cells from the blood of AML patients who had received chemotherapy following their initial diagnosis.
DNT cells can be expanded at different stages of chemotherapy from fresh or frozen/thawed samples
Since all newly diagnosed AML patients undergo several rounds of chemotherapy, the biology and the ability to collect and expand DNT cells might be affected by repeated exposure to cancer immunotherapy using DNT cells S Merims et al chemotherapy. To determine the optimal time for DNT cell expansion and function during chemotherapy, blood samples were drawn from some patients either at 1 month after induction chemotherapy (sample a) or 1 month after repeated courses of consolidation therapies (sample b). There was no significant difference in either the total number of expanded cells ( Figure 2a ) or total number of DNT cells (Figure 2b ) at the different time points examined, indicating that DNT cells can be expanded from the majority of AML patients 1 month after completing induction or consolidation chemotherapy. Next, to determine whether DNT cells can be expanded after freezing and thawing, blood samples were collected from four AML patients and after depleting CD4 þ and CD8 þ cells, half of the enriched DNT cells were expanded and half were frozen viably. The frozen DNT cells were thawed one day later and expanded. When the total cell number and function of expanded DNT cells from fresh or frozen/thawed samples was compared, no statistically significant difference in total cell number or cytolysis of leukemic cells was observed (Figures 2 c-f) . Collectively, these findings indicate that multiple blood samples may be collected for expanding DNT cells during chemotherapy and frozen to be used at later time points when treating patients.
Ex vivo expanded AML patients DNT cells express high levels of IFN-g, TNF-a, perforin and Granzyme B, and are able to kill leukemic cell lines in vitro through perforin-dependant pathway IFN-g expression and in vitro tumor cell cytolysis have been shown to be correlated with the efficacy of adoptively þ and CD8 þ T cells. Aliquots of the remaining cells were stained with anti-CD3-FITC, anti-CD4-PE, anti-CD8-PE and anti-CD56-PECy7. The remaining cells were expanded ex vivo as described in the Materials and methods. On day 14, the expanded cells were harvested and stained as before. Data were analyzed by flow cytometry. Representative dot plots from the same patient before (day 0) and 14 days after ex vivo expansion are shown. A volume of 20 ml whole blood was drawn from 16 AML patients in complete remission at 1 month after induction chemotherapy (a), or 1 month after one (b1) or more (b2) consolidation chemotherapy.
cancer immunotherapy using DNT cells S Merims et al transferred T cells. 21 To evaluate the potential anti-tumor activity of ex vivo expanded DNT cells from AML patients, we first measured the expression level of IFN-g and TNF-a, two well-known cytokines that can contribute to tumor immunity. We found that the majority of expanded DNT cells expressed high levels of intracellular IFN-g and TNF-a, which were similar to or higher than that seen with CD8 þ T cells that were isolated, activated and expanded from the same patient using the same protocol as DNT cells (Figure 3a) .
Next, we assessed whether the ex vivo expanded DNT cells can kill allogeneic leukemic cell lines. Ex vivo expanded DNT cells from AML patients were used as effectors in standard 51 Cr-release assays against the human monocytic leukemic cell line AML-3 or U937. DNT cell cultures containing o70% DNT cells were depleted of contaminating CD4 þ , CD8 þ and CD56 þ cells before cytotoxicity assays were performed. We consistently observed a dose-dependent killing of these leukemic cell lines (Figure 3b) . Furthermore, we found that DNT cell-mediated cytotoxicity of leukemic cells could be effectively blocked by pre-incubation of DNT cells with CMA, which blocks activation of the perforin molecule 22 (Figure 3c ), indicating that perforin has an important role in DNT cellmediated leukemia cytolysis in vitro. Although our expansion protocol resulted in very low frequency of CD3 þ CD56 þ cells (on average 5%, range 2-9%), cultures sometimes contained significant numbers of CD4 þ or CD8 þ T cells. To evaluate the relative contribution of DNT cells versus CD4 þ and CD8 cancer immunotherapy using DNT cells S Merims et al and CD8 þ T cells that were expanded from the same donor and used them as effectors. We found that although each expanded subpopulation displayed an anti-leukemic activity, DNT cells showed higher cytolysis of allogeneic leukemic cells than either CD4 þ and/or CD8 þ T cell subsets. However, when nonexpanded DNT cells or CD4 þ or CD8 þ T cells from the same donor were used as effectors, no significant cytotoxicity was observed (Supplementary Figure 1) . Together, these data demonstrate that the ex vivo expanded DNT cells are cytolytic to allogeneic leukemic cell lines and perforin is critical for DNT cell-mediated cytotoxicity.
AML patients DNT cells are cytotoxic to autologous CD34
þ leukemic cells
To further determine whether ex vivo expanded DNT cells from AML patients could kill autologous primary leukemic cells, leukemic blasts were collected from AML patients at diagnosis. Blood samples were collected after chemotherapy-induced CR and DNT cells were expanded ex vivo. For those patients whose DNT cells could be expanded, CD34 þ cells from their leukemic blasts were purified (Figure 4a ) and used as targets. To exclude an effect of non-DNT populations on cytotoxicity, we first purified DNT cells to greater than 95% by depleting CD4 þ , CD8 þ and CD56 þ cells before their use as effectors. As shown in Figure 4b , six out of seven AML patients that were studied showed varying degrees of cytotoxicity against primary autologous CD34 þ leukemic cells in vitro. These data demonstrated that ex vivo expanded DNT cells from AML patients can kill autologous CD34 þ leukemic blasts. As expanded patient DNT cells contain both ab-and gd-TCR þ DNT cells, we next analyzed the cytolytic activity
À cells were purified by FACS from three AML patients and used as effectors to kill CD34 þ primary leukemia blasts purified from three different AML patients. As shown in Figure 4c , both ab-TCR þ and gd-TCR þ DNT cells showed a dose-dependent cytotoxicity against primary CD34 þ leukemic cells. In two of three cases, cytotoxicity against AML cells by ab-DNT cells compared with gd-DNT cells was similar whereas in one patient gd-TCR þ DNT cells had slightly higher lysis of AML blasts compared with ab-DNT cells. When purified ab-DNT and gd-DNT cell-mediated cytolysis of leukemic blasts was compared with CD3 þ CD4 À CD8 À CD56 À DNT cells, no synergistic effect between ab-TCR þ and gd-TCR þ DNT cells was observed (data not shown). These data demonstrate that ex vivo expanded DNT cells from AML patients can kill primary CD34 þ leukemic blasts in vitro and that both DNT cell subsets contribute to this anti-tumor effect.
Discussion
In this study, we explored the use of ex vivo expanded DNT cells as a novel form of adoptive T-cell therapy. We first developed a novel DNT cell expansion protocol, which includes enrichment of DNT cells by depleting CD4 þ and CD8 þ T cells from the starting population, TCR-crosslinking of enriched DNT cells and timed addition of anti-CD3 monoclonal antibody and cytokines. Using this protocol, we were able to obtain from 24 out of 28 cultures an average of 64 Â 10 6 cells in 2 weeks from only 20 mls of blood collected from AML patients in CR at 1 month after chemotherapy, with the majority being (Figure 3a) , cytokines and molecules that are well-known to have direct and indirect anti-tumor activities. Other studies have shown a significant correlation between the ability of expanded T cells to lyse tumor cells in vitro and clinical outcome. 23, 24 When ex vivo expanded AML patient DNT cells were used as effectors in cytotoxicity assays, we consistently observed a dosedependent killing of leukemic cells in vitro. Moreover, blocking perforin activation in DNT cells abrogated 80-97% of their ability to kill leukemic cells, suggesting that perforin has a major role in DNT cell-mediated cytolysis of tumor cells. Importantly, we used a fully autologous system where both DNT cells and leukemic blasts were derived from the same patient. We demonstrated that purified DNT cells from six out of seven AML patients could kill autologous CD34 þ leukemic blasts isolated from PB of the same patient (Figure 4b) . In contrast, when autologous PB mononuclear cells or activated autologous CD8 þ T cells were used as targets, we did not observe significant DNT cell-mediated cytotoxicity (data not shown). Collectively, these data demonstrate, for the first time, that DNT cells can be expanded from AML patients in CR and have potent antileukemia effects. These findings suggest the possibility of eliminating residual leukemic cells after chemotherapy by infusion of ex vivo expanded autologous DNT cells.
There are several potential advantages of ultilizing this unique adoptive T cell therapy: first, high numbers of DNT cells (up to 15 million/ml blood) could be generated ex vivo in a relatively short period of time. Most protocols used for ex vivo cell expansion for adoptive cellular therapy require between 3 to more than 6 weeks to obtain a sufficient number of cellular products. 10, [25] [26] [27] [28] The expansion technique utilized here has the capacity to produce therapeutic doses of DNT cells in only 2 weeks, which significantly reduces both the cost of cellular production and the chance of contamination, and limits the logistical inconvenience associated with delays that are incurred with autologous cellular production. In addition, the majority of our expanded cells are CD45 RO þ and CD27 þ , which suggests a shorter expansion time favors the production of T cells that are at a central memory stage. 29 This may be clinically relevant as central memory T-cells appear to be more effective in eliminating cancer cells after adoptive transfer than highly differentiated T cells. 24 Second, we were able to expand DNT cells from AML patients in CR within 1 month of receiving dose intensive induction and/or consolidation chemotherapy. This potentially would permit protocols that adoptively transfer DNT cells during or soon after chemotherapy when the tumor cell burden is very low, thus increasing the chance of erradicating MRD. Third, it has been shown that preconditioning patients before adoptive transfer of T lymphocytes with lymphodepletion can enhance their efficacy by eliminating regulatory T cells and endogenous lymphocytes that compete with the transferred cells for homeostatic cytokines, thus facilitating homeostatic expansion of transferred T cells. 21, [30] [31] [32] [33] [34] Recent studies suggest that the greater the depletion of the patient's immune cells, the more effective the treatment of adoptive T-cell transfer against metastatic melanoma. 26, 31 All AML patients receive chemotherapies after diagnosis of the disease. The ability to expand and administer DNT cells during or shortly after standard chemotherapy may facilitate in vivo expansion of DNT cells after adoptive transfer without the need for administering additional preconditioning therapy. Lastly, we showed that DNT cells could be expanded from both fresh or frozen/thawed samples with no significant difference in their expansion rate or anti-tumor ability. It is thus possible to collect multiple blood samples from AML patients while in CR to freeze DNT cells for subsequent expansion so that multiple doses of DNT cells could Cr-release assay with three replicates for each patient. (c) DNT cells were expanded from three AML patients. After 14 days of culture, both ab-
À DNT cells (gd-DNT) were purified by FACS and used separately as effectors. Freshly isolated CD34 þ leukemic blasts from three different AML patients were labeled with 51 Cr and used as targets. Specific killing of CD34 þ cells was determined by standard cytotoxicity assay. Solid lines and dash lines show ab-DNT and gd-DNT cell mediated cytolysis of primary CD34 þ targets, respectively.
cancer immunotherapy using DNT cells S Merims et al be administered to enhance the treatment effect. To be able to expand DNT cells from a frozen sample also provides the flexibility of transporting cells to centers and expanding them under GMP conditions, which may not be available locally. Using the culture conditions developed in this study, we could expand DNT cells from the majority (13/16, 81%) of the patients. However, as was seen with ex vivo expanded cytokineactivated killer cells from leukemia and lymphoma patients, 10, 35 there was a large range in the DNT cell expansion rate among AML patients. Due to the heterogeneity of AML and relatively small number of patients that were studied, we were unable to elicit the factors that determine the expansion rate of DNT cells, although patient age and gender do not appear to impact DNT cell expansion. Interestingly, the highest expansion (300 million DNT cells from 20 ml blood) was obtained from a 65 year-old patient ( Table 1 ). The oldest patient of this cohort study was a 69 year old and the three samples collected at different time points after induction or consolidation chemotherapy from this patient yielded an average of 88.7x10 6 DNT cells from 20 ml blood (Table 1 ). These data suggest the possibility of applying adoptive DNT cell therapy to elderly AML patients during or after chemotherapy to help eliminate MRD. This finding is significant because elderly AML patients have the highest relapse rate and less than 5% survive more than 5 years after diagnosis with conventional chemotherapy and only a minority are candidates for HCT. 36, 37 No correlation was observed between white blood cell counts at the time of diagnosis and DNT cell expansion rate. We also compared the total number of expanded DNT cells between patients with second CR with those in first CR. Although the average expanded cell numbers were higher in non-relapsed patients, the difference was not statistically significant (Table 1) . Future studies in a larger cohort of AML patients could allow us to define factors such as disease type, cytogenetics and previous therapies that predict the ability to successfully expand DNT cells ex vivo.
Many studies have shown that ex vivo expanded autologous CD8 þ T cells, CD4 þ T cells, CD3 þ CD56 þ cells, gd-T cells and natural killer cells can all contribute to anti-tumor activity either alone or in concert. 10, 17, 21, [38] [39] [40] As seen in most reports, our expanded cells are a heterogeneous population with the majority being DNT cells (Supplementary Table 1 ). It is possible that other expanded cell subsets could also contribute to the cytotoxicity against leukemic cells. Nevertheless, the following findings indicate that expanded DNT cells have potent antileukemia effect: when purified DNT cells were compared with CD4 þ or CD8 þ T cells expanded from the same donor in the same assay, DNT cells showed higher cytotoxicity towards allogeneic leukemic cells than CD4 þ and CD8 þ T cells (Supplementary Figure 1 ). More importantly, when CD4 þ , CD8 þ and CD56 þ cells were depleted from expanded cells so that the effector cells comprised on average 95% DNT cells (Supplementary Figure 2 ), we observed dose-dependent killing of primary CD34 þ leukemic blasts (Figures 4b and c) . Together, these data clearly demonstrate that the ex vivo expanded DNT cells from AML patients possess potent anti-leukemia effects in vitro. Future studies should examine the fate and function of each subset of expanded cells in vivo to ensure that they do not exert significant toxicity to cancer patients before using them as autologous cell therapy for cancer.
In summary, we have developed a novel protocol by which DNT cells from AML patients in CR shortly following dose intensive chemotherapy can be purified from PB and expanded ex vivo to doses that would be potentially useful clinically within 2 weeks. We demonstrate, for the first time, that ex vivo expanded DNT cells from patients with AML can effectively kill leukemia cell lines and primary autologous CD34 þ leukemic blasts. Our data highlight the potential of using DNT cells as a novel adjuvant immunotherapy to improve the survival of AML patients by eliminating MRD. Our findings also open a new window for adoptive T-cell therapy of other human cancers.
